Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)

Author(s): Ankur Kumar Upadhyay, Amrendra Kumar Ajay, Sandeep Singh, Manoj Kumar Bhat

Journal Name: Current Cancer Drug Targets

Volume 8 , Issue 8 , 2008

Become EABM
Become Reviewer
Call for Editor


Neuronal cell specific cyclin-dependent kinase 5 (Cdk5) is a known regulator of neurodegenerative disorders such as Alzheimers and Parkinsons diseases. We report that Cdk5 also plays an important role in the proliferation of breast cancer cells MCF-7 and MDA MB-231 and is functionally involved in chemosensitivity as well as in cell death pathways induced by anti-cancer drug carboplatin (Carb). Here, we demonstrate that carboplatin induced Cdk5 activation under positive regulation of ERK, promotes cell death in MCF-7 and MDA MB-231 cells. DNA-damage stress enhanced ERK activity utilizes Cdk5 as one of its downstream targets for the execution of death signal in carboplatin induced death in MCF-7 and MDA MB-231 cells. Additionally, present data clearly indicates that activated Cdk5 modulates p53 transactivation in MCF-7 cells. However, in p53 mutant MDA MB-231 cells, Cdk5 mediated cell death is likely to be p53 independent. Collectively, our findings not only draw attention to the extra-neuronal functions of Cdk5 but also propose Cdk5 as a novel and potential therapeutic target of chemotherapeutic drugs.

Keywords: Carboplatin, Cdk5, ERK, p53

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [741 - 752]
Pages: 12
DOI: 10.2174/156800908786733405
Price: $65

Article Metrics

PDF: 12